This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
OptumRx launched Price Edge, a tool that compares pricing for traditional generic drugs to ensure members get the lowest prescriptiondrugprices. FDA is currently reviewing use of Selux's NGP Gram-Negative panel. Inspira Technologies said it received patent approval from the U.S.
This post updates my initial thoughts on the deal, given the morphing US healthcare market on both the traditional health services front and fast-evolving retail health environment. The nation’s largest retail pharmacy chain signed a deal to combine with one of the top three healthinsurance companies.
voters’ priorities, across political party – prescriptiondrugprices. voters in 2020 quite like supporting Medicare’s ability to negotiate drugprices with pharmaceutical companies, shown by the October 2019 Kaiser Family Foundation Health Tracking Poll. Few issues unite U.S.
This is what happened to pharma stock prices on Friday after President Trump and Secretary of Health and Human Services Alex Azar outlined their new policies focusing on prescriptiondrugprices. The graph is the Nasdaq U.S.
Health Care Post #Election2024,” I’ll focus on U.S. consumer dissatisfaction with drugprices — across political party identification. Let’s set the context with data from a recently-published study from Navitus Health Solutions exploring 2,000 U.S. than anywhere else in the world.
We organize all of the trending information in your field so you don't have to. Join 26,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content